Erratum: Progestin and breast cancer: The missing pieces of a puzzle (Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz (2008) 51 (782-786) DOI: 10.1007/s00103-008-0586-6);Progestin and breast cancer. The missing pieces of a puzzle

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 51, Issue 7, 2008, Pages 782-786

  Giersig, Cecylia ^a,b  

^a Federal Institute for Drugs and Medical Devices   (Germany)

^b Bundesinstitut fur Arzneimittel und Medizinproducte   (Germany)

Author keywords

Breast cancer risk; Combined oral contraceptives; Contraceptives; Progestin; Progestin only contraceptives

Indexed keywords

EID: 46649119493     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-008-0637-z     Document Type: Erratum

References (21)

1. Liang Y, Besch-Williford C, Brekken RA, Hyder SM (2007) Progestin-dependent progression of human breast tumour xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 67(20):9929-9936
2. Jovanovic Poole A, Li Y, Kim Y, et al. (2006) Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467-1470
3. Wiebe JP (2006) Progesterone metabolites in breast cancer. Endocrine Related Cancer 13:717-738
4. Wiebe JP, Souter L, Zhang G (2006) Dutasteride affects progesterone metabolizing enzyme activity/ expression in human breast cell lines resulting in suppression of cell proliferation and detachment J Steroid Biochem Mol Biol 100(4-5):129-140
5. Wiebe JP, Lewis MJ, Cialacu V, et al. (2005) The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol 93(2-5):201-208
6. Maayan R, Fisch B, Galdor M, et al. (2004) Influence of 17beta-estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women. Brain Res 1020(1-2):167-172
7. Liang T, Liao S (1992) Inhibition of steroid 5xreductase by specific aliphatic unsaturated fatty acids. Biochem J 285:557-562
8. Chajes V, Sattler W, Stranzl A, Kostner GM (1995) Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and Vitamin-E. Breast Cancer Res Treatment 34:199-212
9. Jiang WG, Singhrao SK, Hiscox S, et al. (1997) Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Clin Exp Metastasis 15:593-602
10. Moore MR, Spence JB, Kiningham KK, Dillon JL (2006) Progestin inhibition of cell death in human breast cancer cell lines. Journal of Steorid Biochemistry & Molecular Biology 98(4-5):218-227
11. Zylka-Menhorn V (2007) Rückgang der Brustkrebsinzidenz:.,Eine Kausalität lässt sich aus den Daten nicht sicher ableiten". Dtsch Ärztebl 104:C16-17
12. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333
13. Women's Health Initiative Randomized Trial (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289:3243-3253
14. The Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 291:1701-1712
15. Persson I, Weiderpass E, Bergkvist L, et al. (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10(4):253-260
16. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713-1727
17. Milne RL, Knight JA, John EM, et al. (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers 14(2):350-356
18. Shapiro S, Rosenberg L, Hoffman M, et al. (2000) Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151(4):396-403
19. Kumle M, Weiderpass E, Braaten T, et al. (2002) Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 11(11):1375-1381
20. Backman T, Rauramo I, Jaakkola K, et al. (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106(4):813-817
21. Agrawal G, Chen JH, Baick CH, et al. (2007) Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy. J Clin Oncol 25(18):2618-2660